Prediction of CCND1 Amplification Using Plasma DNA As a Prognostic Marker in Oesophageal Squamous Cell Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2010 Apr 15

PMID 20389301

Citations 12

Authors

H Takeshita

D Ichikawa

S Komatsu

M Tsujiura

T Kosuga

K Deguchi

H Konishi

R Morimura

A Shiozaki

H Fujiwara

K Okamoto

E Otsuji

Affiliations

Soon will be listed here.

Abstract

Background: We aimed to develop a new biomarker to predict cyclin D1 (CCND1) status using plasma DNA in oesophageal squamous cell carcinoma (ESCC) patients.

Methods: We evaluated the ratio of the CCND1 (11q13) dosage to the dopamine receptor D2 (DRD2; 11q22-23) dosage (C/D ratio) as CCND1 copy number. This study was divided into three steps: (1) Determination of a cutoff value for the C/D ratio in test scale; (2) Comparison of the C/D ratio in between plasma samples and cancer tissues in ESCC patients showing high plasma C/D ratio; (3) Validation study of the clinical application of the plasma C/D ratio as a diagnostic and prognostic marker, by comparing with clinicopathologic factors in 96 ESCC patients.

Results: The plasma C/D ratio was significantly higher in the ESCC group than the controls (P=0.0134). A high plasma C/D ratio reflected the tumour C/D ratio, and significantly correlated with a poorer prognosis (P=0.0186). Moreover, the high C/D ratio was found to be an independent prognostic factor on multivariate analysis (P=0.0266; hazard ratio 5.988).

Conclusion: Prediction of CCND1 amplification using plasma DNA is thought to be a promising prognostic biomarker in ESCC patients.

Citing Articles

Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective.

Mishra S, Kumari S, Husain N J Liq Biopsy. 2025; 6:100280.

PMID: 40027313 PMC: 11863890. DOI: 10.1016/j.jlb.2024.100280.

Comparative Genomic Analysis Reveals Genetic Variations in Multiple Primary Esophageal Squamous Cell Carcinoma of Chinese Population.

Liang J, Wang Y, Cai L, Liu J, Yan J, Chen X Front Oncol. 2022; 12:868301.

PMID: 35515115 PMC: 9065449. DOI: 10.3389/fonc.2022.868301.

Circulating tumor DNA analysis in the era of precision oncology.

Said R, Guibert N, Oxnard G, Tsimberidou A Oncotarget. 2020; 11(2):188-211.

PMID: 32010431 PMC: 6968778. DOI: 10.18632/oncotarget.27418.

FAM175B promotes apoptosis by inhibiting ATF4 ubiquitination in esophageal squamous cell carcinoma.

Zhao Y, Yu Y, Li H, Zhang Z, Guo S, Zhu S Mol Oncol. 2019; 13(5):1150-1165.

PMID: 30854784 PMC: 6487841. DOI: 10.1002/1878-0261.12474.

Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.

Koldby K, Mortensen M, Detlefsen S, Pfeiffer P, Thomassen M, Kruse T J Gastroenterol. 2018; 54(2):108-121.

PMID: 30242476 DOI: 10.1007/s00535-018-1508-5.

References

Fleischhacker M, Schmidt B . Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta. 2006; 1775(1):181-232. DOI: 10.1016/j.bbcan.2006.10.001. View

Ichikawa D, Koike H, Ikoma H, Ikoma D, Tani N, Otsuji E . Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res. 2004; 24(4):2477-81. View

Gotoh T, Hosoi H, Iehara T, Kuwahara Y, Osone S, Tsuchiya K . Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol. 2005; 23(22):5205-10. DOI: 10.1200/JCO.2005.02.014. View

Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C . Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003; 21(21):3902-8. DOI: 10.1200/JCO.2003.02.006. View

Enzinger P, Mayer R . Esophageal cancer. N Engl J Med. 2003; 349(23):2241-52. DOI: 10.1056/NEJMra035010. View

Lam A . Molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol. 2000; 33(2):71-90. DOI: 10.1016/s1040-8428(99)00054-2. View

Tomita H, Ichikawa D, Ikoma D, Sai S, Tani N, Ikoma H . Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res. 2007; 27(4C):2737-41. View

Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B . Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res. 2006; 12(13):3915-21. DOI: 10.1158/1078-0432.CCR-05-2324. View

Hollstein M, Metcalf R, Welsh J, Montesano R, Harris C . Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A. 1990; 87(24):9958-61. PMC: 55293. DOI: 10.1073/pnas.87.24.9958. View

10.

Imoto I, Yang Z, Pimkhaokham A, Tsuda H, Shimada Y, Imamura M . Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. 2001; 61(18):6629-34. View

11.

Hiyama T, Yoshihara M, Tanaka S, Chayama K . Genetic polymorphisms and esophageal cancer risk. Int J Cancer. 2007; 121(8):1643-58. DOI: 10.1002/ijc.23044. View

12.

Kyomoto R, Kumazawa H, Toda Y, Sakaida N, Okamura A, Iwanaga M . Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma. Int J Cancer. 1998; 74(6):576-81. DOI: 10.1002/(sici)1097-0215(19971219)74:6<576::aid-ijc3>3.0.co;2-r. View

13.

Skvortsova T, Rykova E, Tamkovich S, Bryzgunova O, Starikov A, Kuznetsova N . Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer. 2006; 94(10):1492-5. PMC: 2361269. DOI: 10.1038/sj.bjc.6603117. View

14.

Shinozaki H, Ozawa S, Ando N, Tsuruta H, Terada M, Ueda M . Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res. 1996; 2(7):1155-61. View

15.

Schwarzenbach H, Alix-Panabieres C, Muller I, Letang N, Vendrell J, Rebillard X . Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res. 2009; 15(3):1032-8. DOI: 10.1158/1078-0432.CCR-08-1910. View

16.

Komatsu S, Imoto I, Tsuda H, Kozaki K, Muramatsu T, Shimada Y . Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis. 2009; 30(7):1139-46. DOI: 10.1093/carcin/bgp116. View

17.

Adelaide J, Monges G, Derderian C, Seitz J, Birnbaum D . Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br J Cancer. 1995; 71(1):64-8. PMC: 2033462. DOI: 10.1038/bjc.1995.13. View

18.

Sato-Kuwabara Y, Neves J, Fregnani J, Sallum R, Soares F . Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer. 2009; 9:6. PMC: 2648997. DOI: 10.1186/1471-2407-9-6. View

19.

Chiang P, Beer D, Wei W, Orringer M, Kurnit D . Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. Clin Cancer Res. 1999; 5(6):1381-6. View

20.

Koike H, Ichikawa D, Ikoma H, Otsuji E, Kitamura K, Yamagishi H . Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients. J Surg Oncol. 2004; 87(4):182-6. DOI: 10.1002/jso.20106. View